Abstract
This collection of review articles highlights the latest development of antithrombotics and provides proven experimental methods for the further development of new and improved anticoagulants. Among the cutting-edge developments reviewed are the novel usage of low molecular weight heparins, such antithrombin agents as the hirudin, and such antiplatelet drugs as the GPIIb IIIa inhibitors and ADP receptor antagonists. Additional innovations discussed include aspirin and clopidogrel, the expanded use of polytherapeutic approaches, antiproteases (factors IIa, Xa, and VIIa), tissue factor targeting, platelet receptor targeting, and antithrombin III modulation.

From Book News, Inc.
This practical collection provides a comprehensive update on clinically relevant in vitro and in vivo models of thrombosis and hemostasis for the discovery and testing of antithrombotics, and summarizes recent development in pharmaceuticals for the prevention and treatment of various thromboembolic disorders. Topics of the 17 contributions include low molecular weight heparins, antithrombotic drugs for the treatment of heparin-induced thrombocytopenia, guidelines for the diagnosis of deep venous thrombosis and pulmonary embolism, the development of both small and large animal models, the characteristics of factor Xa inhibitors, and the development of therapeutic candidates based on cell adhesion molecules.Copyright 2004 Book News, Inc., Portland, OR

Book Info
Albany College of Pharmacy, New York. Highlights the latest developments in antithrombotics and provides experimental methods for the discovery of new and improved anticoagulants. Presents relevant in vitro and in vivo models in thrombosis and hemostasis. For researchers and clinicians. DNLM: Anticoagulants--therapeutic use.